Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.

Tytuł:: Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.
Autorzy:: Busschots D; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500, Hasselt, Belgium. .; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium. .
Kremer C; Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-Biostat), Data Science Institute, Hasselt University, Diepenbeek, Belgium.
Bielen R; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500, Hasselt, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Koc ÖM; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500, Hasselt, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Medical Microbiology, School of NUTRIM, Maastricht University Medical Centre, Maastricht, the Netherlands.
Heyens L; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500, Hasselt, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; School of NUTRIM, Maastricht University Medical Centre, Maastricht, the Netherlands.
Nevens F; Department of Gastroenterology and Hepatology, University Hospitals KU, Leuven, Belgium.
Hens N; Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-Biostat), Data Science Institute, Hasselt University, Diepenbeek, Belgium.; Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Robaeys G; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Diepenbeek, 3500, Hasselt, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals KU, Leuven, Belgium.
Źródło:: BMC public health [BMC Public Health] 2022 Nov 24; Vol. 22 (1), pp. 2159. Date of Electronic Publication: 2022 Nov 24.
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, [2001-
MeSH Terms:: Hepatitis C, Chronic*
Hepatitis C*/epidemiology
Prisoners*
Humans ; Hepacivirus ; Prevalence ; Antiviral Agents ; Hepatitis C Antibodies
References:: Public Health Rep. 2021 Nov-Dec;136(6):726-735. (PMID: 33602004)
Trop Med Int Health. 2018 Jun;23(6):641-649. (PMID: 29698576)
BMC Infect Dis. 2021 Jun 16;21(1):584. (PMID: 34134657)
Arch Iran Med. 2019 Oct 01;22(10):588-591. (PMID: 31679361)
Public Health Rep. 2017 Jan/Feb;132(1):41-47. (PMID: 28005477)
EClinicalMedicine. 2020 Oct 05;27:100567. (PMID: 33150329)
J Infect Public Health. 2013 Jun;6(3):186-95. (PMID: 23668463)
J Hepatol. 2016 Dec;65(6):1094-1103. (PMID: 27520879)
Liver Int. 2013 Feb;33 Suppl 1:68-79. (PMID: 23286849)
J Urban Health. 2015 Apr;92(2):379-86. (PMID: 25795212)
Lancet. 2011 Aug 13;378(9791):571-83. (PMID: 21802134)
J Viral Hepat. 2017 Sep;24(9):733-741. (PMID: 28256027)
J Hepatol. 2014 Nov;61(1 Suppl):S45-57. (PMID: 25086286)
Curr HIV/AIDS Rep. 2020 Feb;17(1):18-25. (PMID: 31933274)
Euro Surveill. 2019 Apr;24(14):. (PMID: 30968825)
Res Synth Methods. 2019 Sep;10(3):476-483. (PMID: 30945438)
Hepatology. 2016 Nov;64(5):1821-1822. (PMID: 27118063)
Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1206-1214. (PMID: 28914697)
Lancet. 2016 Sep 10;388(10049):1089-1102. (PMID: 27427453)
Int J Drug Policy. 2021 Apr;90:103055. (PMID: 33310637)
Public Health Rep. 2017 Nov/Dec;132(6):617-621. (PMID: 29045799)
Diagnostics (Basel). 2021 May 14;11(5):. (PMID: 34068955)
Drug Alcohol Depend. 2017 Dec 1;181:140-145. (PMID: 29054033)
Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):24-9. (PMID: 23563821)
Rev Esp Enferm Dig. 2019 Jul;111(7):550-555. (PMID: 31215210)
Drug Alcohol Depend. 2015 Jun 1;151:68-75. (PMID: 25861943)
Health Justice. 2017 Oct 30;5(1):10. (PMID: 29086078)
BMC Infect Dis. 2019 Nov 9;19(1):955. (PMID: 31706284)
Health Policy. 2018 Dec;122(12):1392-1402. (PMID: 30392782)
Int J Drug Policy. 2016 Nov;37:9-20. (PMID: 27455177)
Iran J Public Health. 2014 Feb;43(2):229-34. (PMID: 26060747)
Open Forum Infect Dis. 2020 Jul 17;7(8):ofaa301. (PMID: 32818142)
Int J Prison Health. 2014;10(3):164-71. (PMID: 25764176)
J Clin Virol. 2019 Apr;113:20-23. (PMID: 30825832)
Hepatology. 2013 Oct;58(4):1215-24. (PMID: 23504650)
J Viral Hepat. 2020 Apr;27(4):449-452. (PMID: 31749225)
PLoS One. 2017 Jan 6;12(1):e0169195. (PMID: 28060860)
J Blood Med. 2021 Jul 05;12:561-570. (PMID: 34267568)
J Viral Hepat. 2019 Jan;26(1):101-108. (PMID: 30315691)
BMC Gastroenterol. 2020 Oct 30;20(1):360. (PMID: 33126856)
BMC Infect Dis. 2014;14 Suppl 6:S17. (PMID: 25252822)
PLoS One. 2019 Jul 26;14(7):e0220297. (PMID: 31348813)
Public Health Rep. 2014 Jan-Feb;129 Suppl 1:5-11. (PMID: 24385643)
N Engl J Med. 2014 May 15;370(20):1871-4. (PMID: 24827032)
Can J Public Health. 2018 Jun;109(3):353-361. (PMID: 29981093)
BMC Infect Dis. 2018 Jul 21;18(1):339. (PMID: 30031373)
Harm Reduct J. 2020 Aug 14;17(1):56. (PMID: 32795371)
J Public Health (Oxf). 2020 May 26;42(2):423-428. (PMID: 32090269)
J Public Health (Oxf). 2016 Mar;38(1):130-7. (PMID: 25736438)
PLoS One. 2015 Jul 20;10(7):e0131718. (PMID: 26192811)
Am J Public Health. 2014 Sep;104(9):1722-7. (PMID: 25033142)
J Health Care Poor Underserved. 2014 May;25(2):652-62. (PMID: 24858874)
BMC Public Health. 2019 Jan 8;19(1):30. (PMID: 30621658)
BMC Infect Dis. 2016 Jun 06;16:249. (PMID: 27267370)
Euro Surveill. 2013 Jul 11;18(28):. (PMID: 23870097)
Am J Gastroenterol. 2018 Nov;113(11):1639-1648. (PMID: 29946175)
AIDS Res Hum Retroviruses. 2017 Jun;33(6):524-533. (PMID: 28094553)
PLoS One. 2017 Jul 7;12(7):e0180646. (PMID: 28686715)
Ceylon Med J. 2015 Mar;60(1):18-20. (PMID: 25804913)
Med J Aust. 2014 Mar 17;200(5):277-80. (PMID: 24641153)
J Viral Hepat. 2020 Dec;27(12):1430-1436. (PMID: 32813904)
Public Health Rep. 2016 May-Jun;131 Suppl 2:98-104. (PMID: 27168668)
Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):790-799. (PMID: 34446261)
J Infect Dev Ctries. 2013 Jun 15;7(6):453-67. (PMID: 23771289)
PLoS One. 2013;8(3):e59643. (PMID: 23527238)
BMJ Open. 2014 Oct 19;4(10):e005694. (PMID: 25331969)
J Viral Hepat. 2018 Nov;25(11):1260-1269. (PMID: 29851232)
BMC Public Health. 2019 May 10;19(Suppl 3):466. (PMID: 32326938)
Am J Prev Med. 2019 Jan;56(1):8-16. (PMID: 30467088)
Int J Drug Policy. 2020 Jan;75:102608. (PMID: 31759307)
Public Health Rep. 2019 Nov/Dec;134(6):626-633. (PMID: 31530093)
Int J STD AIDS. 2015 Feb;26(2):120-7. (PMID: 24733152)
BMJ Open. 2020 Sep 6;10(9):e037045. (PMID: 32895275)
Arch Iran Med. 2019 Sep 01;22(9):501-504. (PMID: 31679371)
PLoS One. 2019 Jun 26;14(6):e0218482. (PMID: 31242210)
Hepat Mon. 2016 Dec 03;16(12):e31541. (PMID: 28123439)
BMC Public Health. 2013 Oct 20;13:981. (PMID: 24139133)
BMC Infect Dis. 2018 Oct 29;18(1):539. (PMID: 30373535)
Coll Antropol. 2014 Jun;38(2):417-22. (PMID: 25144968)
Addiction. 2013 Jul;108(7):1296-304. (PMID: 23297816)
Hippokratia. 2009 Oct;13(4):211-5. (PMID: 20011084)
Rev Soc Bras Med Trop. 2019 Jul 18;52:e20190143. (PMID: 31340375)
PLoS One. 2014 Feb 28;9(2):e90560. (PMID: 24587394)
J Infect Public Health. 2014 Nov-Dec;7(6):517-21. (PMID: 25182508)
BMC Infect Dis. 2021 Jul 27;21(1):708. (PMID: 34315415)
Med Glas (Zenica). 2017 Feb 1;14(1):73-78. (PMID: 28165441)
BMC Public Health. 2019 Dec 4;19(1):1631. (PMID: 31801496)
Int J Prison Health. 2019 Jun 10;15(2):162-167. (PMID: 31172859)
Int J Prison Health. 2019 Aug 29;15(3):244-249. (PMID: 31329037)
Eur J Public Health. 2016 Feb;26(1):122-8. (PMID: 26454876)
Dig Liver Dis. 2020 May;52(5):541-546. (PMID: 32234417)
J Ayub Med Coll Abbottabad. 2015 Oct-Dec;27(4):794-7. (PMID: 27004325)
Hepatology. 2013 Apr;57(4):1333-42. (PMID: 23172780)
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):628-637. (PMID: 34171267)
Public Health Rep. 2016 Jul-Aug;131(4):544-51. (PMID: 27453598)
J Correct Health Care. 2016 Jan;22(1):41-5. (PMID: 26672118)
Harm Reduct J. 2020 Oct 20;17(1):80. (PMID: 33081794)
Harm Reduct J. 2018 May 11;15(1):25. (PMID: 29751763)
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):533-546. (PMID: 33965006)
Jundishapur J Microbiol. 2016 Feb 13;9(2):e31598. (PMID: 27127594)
Contributed Indexing:: Keywords: Global health; Hepatitis c; Incarcerated setting; Meta-analysis; Prevalence
Substance Nomenclature:: 0 (Antiviral Agents)
0 (Hepatitis C Antibodies)
Entry Date(s):: Date Created: 20221124 Date Completed: 20221125 Latest Revision: 20221127
Update Code:: 20240104
PubMed Central ID:: PMC9685883
DOI:: 10.1186/s12889-022-14623-6
PMID:: 36419013
: Czasopismo naukowe

Pełny tekst

Background: The introduction of highly effective direct-acting antiviral therapy has changed the hepatitis C virus (HCV) treatment paradigm. However, a recent update on HCV epidemiology in incarcerated settings is necessary to accurately determine the extent of the problem, provide information to policymakers and public healthcare, and meet the World Health Organization's goals by 2030. This systematic review and meta-analysis were performed to determine the prevalence of HCV Ab and RNA in incarcerated settings.
Methods: For this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and Web of Science for papers published between January 2013 and August 2021. We included studies with information on the prevalence of HCV Ab or RNA in incarcerated settings. A random-effects meta-analysis was done to calculate the pooled prevalence and meta-regression to explore heterogeneity.
Results: Ninety-two unique sources reporting data for 36 countries were included. The estimated prevalence of HCV Ab ranged from 0.3% to 74.4%. HCV RNA prevalence (available in 46 sources) ranged from 0% to 56.3%. Genotypes (available in 19 sources) 1(a) and 3 were most frequently reported in incarcerated settings. HCV/HIV coinfection (available in 36 sources) was highest in Italy, Estonia, Pakistan, and Spain. Statistical analysis revealed that almost all observed heterogeneity reflects real differences in prevalence between studies, considering I 2 was very high in the meta-analysis.
Conclusions: HCV in incarcerated settings is still a significant problem with a higher prevalence than in the general population. It is of utmost importance to start screening for HCV (Ab and RNA) in incarcerated settings to give clear, reliable and recent figures to plan further treatment. This is all in the context of meeting the 2030 WHO targets which are only less than a decade away.
Trial Registration: PROSPERO: CRD42020162616.
(© 2022. The Author(s).)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja